Roche bids to broaden MS pipeline and strengthen Ocrevus influence
Data at ECTRIMS will help back fenebrutinib as a potential addition to Roche’s arsenal of drugs, and help cement Ocrevus’s standing.
Autoimmune Disorders
AbbVie extends Rinvoq exclusivity by four years after generics settlements
Otsuka to acquire Cantargia’s CAN10 for autoimmune diseases
IGI and AbbVie sign licence deal for cancer and autoimmune therapy
Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP
Vor Bio back from brink with autoimmune drug deal rising to $4bn
US FDA approves GSK’s Benlysta autoinjector for lupus nephritis
Harbour BioMed partners Otsuka on new T-cell therapy
